Effects of Phase III Cardiac Rehabilitation on Mortality and Cardiovascular Events in Elderly Patients With Stable Coronary Artery Disease

Access this Article

Search this Article

Author(s)

    • ONISHI Tomo
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • SHIMADA Kazunori
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • SEKI Eriko
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • WATANABE Yoshiro
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • SUNAYAMA Satoshi
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • OHMURA Hirotoshi
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • MASAKI Yoshiyuki
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • NISHITANI Miho
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • FUKAO Kosuke
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • KUME Atsumi
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • MOKUNO Hiroshi
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • KAWAI Sachio
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine
    • DAIDA Hiroyuki
    • Department of Cardiovascular Medicine, Juntendo University School of Medicine

Abstract

<b><i>Background:</i></b> Cardiac rehabilitation (CR) has numerous benefits, including reduction of mortality and cardiovascular events, in patients with coronary artery disease (CAD). However, the long-term effect of phase III CR in elderly patients with stable CAD is still unknown. <b><i>Methods and Results:</i></b> The 111 elderly male CAD patients (≥65 years), including 37 subjects participating in supervised CR for 6 months and 74 age-matched controls, were analyzed. The patients were followed for up to 3,500 days, until the occurrence of death or 1 of the following major adverse cardiovascular events (MACE): cardiovascular death, acute coronary syndrome, refractory angina requiring revascularization, admission for congestive heart failure, or stroke. All-cause mortality tended to be lower in the CR group than in the Control group (14% vs 28%, P=0.081). The MACE incidence was significantly lower in the CR group than in the Control group (30% vs 62%, P=0.001). Multivariate Cox proportional hazard analysis showed that the MACE incidence was significantly lower in the CR group than in the Control group [adjusted hazard ratio 0.43 (95% confidence interval 0.20-0.91), P=0.027]. <b><i>Conclusions:</i></b> Phase III CR has the beneficial effect of reducing cardiovascular events even in elderly patients with stable CAD. (<i>Circ J</i> 2010; <b>74:</b> 709-714)<br>

Journal

  • Circulation Journal

    Circulation Journal 74(4), 709-714, 2010-03-25

    The Japanese Circulation Society

References:  27

Cited by:  1

Codes

  • NII Article ID (NAID)
    10026472427
  • NII NACSIS-CAT ID (NCID)
    AA11591968
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13469843
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top